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Primary pseudohypoaldosteronism type 1 (PHA-1) is a heterogeneous syndrome characterised by salt-wasting due to 
unresponsiveness of target organ to mineralocorticoids. It is inherited in an autosomal recessive or autosomal dominant pattern, 
and often is a result of the mutation de novo. It can be sub-classified into two distinguishable clinical entities: renal PHA type 1 
(renal PHA-1) and multiple PHA type 1 (multiple PHA-1). Secondary (transient) PHA type 1 is usually associated with urinary tract 
infections complicating structural urinary tract anomalies. PHA type 2 (PHA-2, Gordon syndrome) is an entity inherited in an 
autosomal dominant pattern.
Three cases of PHA, two with renal PHA-1 and one with secondary PHA type 1, are reported.
In all patients with salt-wasting and dehydration differentiation between congenital adrenal hyperplasia and PHA should be 
performed. Also, in the case with hyperkalaemia, hyponatremia and metabolic acidosis, urinary tract infection and obstructive 
uropathy should be excluded.
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Introduction
Primary pseudohypoaldosteronism type 1 (PHA-1), first 
described in 1958 by Cheek and Perry,1 is a heterogeneous 
syndrome characterised by salt-wasting due to target organ 
unresponsiveness to mineralocorticoids. It is inherited in an 
autosomal recessive or autosomal dominant pattern, and rarely 
as a result of the mutation de novo.2 The clinical expression of 
PHA-I varies widely, but usually occurs in the neonatal period 
with hyperkalaemia, hyponatremia, metabolic acidosis and 
elevated levels of renin and aldosterone in the blood. It can be 
sub-classified into two distinguishable clinical entities: renal PHA 
type 1 (renal PHA-1) and multiple PHA type 1 (multiple PHA-1) 
(Table 1).3,4
Renal PHA-1 is inherited in an autosomal dominant pattern. Due 
to mutation of the gene that encodes mineralocorticoid 
receptors, aldosterone cannot bind to its receptors. More than 50 
genotypes with no significant correlation to clinical phenotypes 
have been described. Its clinical expression is highly variable. The 
mild form is the most frequent, with spontaneous remission 
within 1–3  years as a result of the maturation of renal salt 
conservation ability.3,5
Multiple PHA-1, caused by mutation of the epithelial sodium 
channel (ENaC) gene, is inherited in an autosomal recessive 
pattern. A defect in sodium transport in many organs, including 
lungs, kidneys, colon, salivary and sweat glands, is present. 
Clinical expression is usually severe, with salt-waste episodes 
starting soon after birth and lasting into adulthood. The 
incidence of lower respiratory tract infections in this population 
is usually higher.6
Secondary (transient) PHA type 1 is usually associated with 
urinary tract infections complicating structural urinary tract 
anomalies.7–9
PHA type 2 (PHA-2) (Gordon syndrome) is an entity inherited in 
an autosomal dominant pattern. Its main clinical features are 
short stature and arterial hypertension (Table 1).10,11
Three cases of PHA, two with renal PHA-1 and one with secondary 
type 1 PHA, have been reported.
Case reports
Case one
A 14-day-old newborn female presented with a history of poor 
feeding, coughing and dyspnoea without temperature instability 
commencing two days prior to hospital admission. She was born 
at term, birth weight 2740 g (25th percentile). Both prenatal and 
postnatal courses as well as family history were uneventful. On 
admission, the baby was pale, dyspnoeic, heart rate 110–145/
min, oxygen saturation 91–95%, with reduced adipose tissue 
and body weight 2500 g (240 g below the birth weight). Chest 
examination revealed numerous early and late inspiratory 
crackles bilaterally, and neurological examination showed axial 
and segmental hypotonia. The main laboratory findings are 
given in Table 2. Fractional excretion of sodium in the urine was 
increased (19.2%) despite the concomitant presence of 
hyponatremia. Cortisol and 17-OH progesterone levels were 
normal. Chest X-ray revealed right-sided pneumonia. Head and 
abdominal ultrasound were normal.
On admission, parenteral antibiotics and parenteral salt 
supplementation were introduced. Within 24 h electrolyte 
imbalance was corrected and no sodium supplementation was 
required thereafter. Clinical and laboratory signs of lower 
respiratory tract infection gradually improved. After 
hospitalisation, the child was fed with infant formula, gain in 
bodyweight was satisfactory, and psychomotor development 
was normal. The serum sodium values were in the normal 
reference range (135  mmol/l), with no additional sodium 
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supplementation. At the age of five months aldosterone and 
plasma renin activity (PRA) values were still above standard 
reference values, but lower than those on admission (Table 2).
Case two
A six-week-old previously healthy male infant was admitted with 
a three day history of loose stools, low-grade fever and decreased 
urine output. He was born at term, birth weight 4000  g (50th 
percentile). Both prenatal and postnatal courses as well as family 
history were uneventful. On admission, the infant was alert with 
a high-pitched cry, pale, heart rate 136/min, respiratory rate 46/
min, oxygen saturation 98%. His bodyweight was 4300  g (< 3 
percentile), skin turgor was decreased and subcutaneous 
adipose tissue was reduced. On physical examination, only axial 
hypotonia with segmental hypertonia was noticed. The initial 
laboratory findings are shown in Table 1. Urine analysis was 
normal. Blood, stool and urine cultures were negative. Cortisol 
and 17-OH progesterone levels were normal, as well as a sweat-
chloride test. Chest X-ray, and head and abdominal ultrasound 
were normal.
On admission, parenteral antibiotics, rehydration and salt 
supplementation were introduced. After two saline boluses, the 
infant started to void urine. Within 48 h renal function and serum 
electrolyte values were normal. After discontinuation of 
parenteral salt supplementation, mild hyponatremia and 
potassium levels in the upper range of reference levels with 
polyuria were noticed, and oral sodium supplements were 
introduced (+1 g NaCl/day). Serum electrolyte values remained 
in the reference ranges thereafter. The aldosterone value was 
normalised by the age of one year, but the PRA level remained 
slightly higher until the age of 18  months (Table 2), when salt 
supplementation was discontinued. The child has normal 
bodyweight and normal psychomotor development.
Case three
A male, previously healthy 22-day-old newborn presented with a 
history of poor feeding and hypotonia. He was born at term, his 
amniotic fluid was meconium-stained, the Apgar score was 
seven in the first minute and nine in the fifth minute and 
birthweight 3720 g (50th percentile). On admission the newborn 
was pale, alert, hypothermic (rectal temperature 35.1°C), heart 
rate 136/min, respiratory rate 30/min, oxygen saturation 98–
100%, bodyweight 3300 g (420 g less than the birthweight). Skin 
turgor was decreased and subcutaneous adipose tissue reduced. 
On physical examination only axial and segmental hypotonia 
were noticed.
The initial laboratory findings are given in Table 1. Urine analysis 
revealed proteinuria (5+), pyuria (4+), urine culture was found to 
be positive (> 100 000 colonies/mm3 of Escherichia coli). Blood 
and cerebrospinal fluid cultures were negative. Cortisol and 17-
OH progesterone levels were normal, as well as a sweat-chloride 
test. On abdominal ultrasound, right kidney ‘pyelon’ diameter 
was 12 x 8 mm with calices up to 5 mm. The left kidney presented 
with a slightly accentuated canalicular system with calices of up 
to 5  mm. Chest X-ray, brain ultrasound, echocardiography and 
electroencephalogram were normal.
Table 1: Characteristics of different types of PHA
Characteristics Renal PHA-1 Multiple PHA-1 PHA-2
Affected organs Kidney Kidney, sweat and salivary glands, colon Kidney
Clinic manifestations From asymptomatic to failure to thrive 
due to chronic dehydration
Severe dehydration, failure to thrive, 
pulmonary infections
Hypertension, short stature
Inheritance (genes) Autosomal dominant (NR3C2) Autosomal recessive (SCNN1A, SCNN1B, 
SCNN1G)
Autosomal dominant (WNK1, WNK4)
Salt-wasting Variable Severe No
PRA and aldosterone concentration Very high, PRA decreases with age Very high (lifelong) Decreased renin, normal aldosterone
Treatment Salt supplementation, 1–3 years (or less) Lifelong salt supplementation,  
potassium-binding resins
Low-dose thiazide diuretics
Prognosis Improvement with age Absent improvement with age ?
Table 2: Summary of cases with initial and control biochemistry and therapy
Notes: RR = reference range; mmol/l-millimoles per litre; μmol/l = micromoles per litre; ng/dl = nanogram per decilitre; μIU/ml = microInternational Units per millilitre.
Factor Case 1 Case 2 Case 3
Age at presentation (days) 14 42 22
Symptoms Poor feeding, weight loss, cough Weight loss, oliguria Weight loss, poor feeding, seizures
Plasma sodium (mmol/l) (RR 135–145) 115 128 108
Plasma potassium (mmol/l) (RR3.5–5) 7.9 7.11 9.9
Plasma HCO3 (mmol/l) (RR 17–25) 24.2 13.7 10.9
pH 7.17 7.31 7.13
Creatinine (μmol/l) 56.2 (normal) 78.8 (mild elevation) 440 (severe elevation)
Serum aldosterone (ng/dl) (RR neonate 
17–154; infant 6.5–86)
−290—at admission; 200—5 months −171—at admission; 128—7 months; 
46—1 year; 7.1—1.5 year
−198.2—at admission; 100—3 months
PRA (μIU/ml) (2.8–39.9) −72—at admission; 52—5 months −330.1—at admission; 112.8—
7 months; 57.9—1 year; 37.3—1.5 year
−89.8—at admission; 11.2—3 months
Sodium supplementation 1 day 1.5 year 1 day (peritoneal dialysis afterwards)
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On admission, parenteral rehydration, salt supplementation and 
parenteral antibiotic therapy were introduced. Hyperkalaemia 
was treated with salbutamol inhalations, sodium bicarbonate 
and continuous insulin infusion. Peritoneal dialysis was started 
because of persistence of electrolyte imbalance and anuria. On 
the second day of treatment electrolyte homeostasis was 
achieved, followed by gradual improvement of renal function 
and normalisation of diuresis. Peritoneal dialysis was stopped on 
the fifth day of treatment. A second urine culture was negative. 
Although antibiotic prophylaxis was introduced on hospital 
discharge, the patient subsequently had two episodes of urinary 
tract infections. During these episodes, blood electrolytes 
including potassium level remained in reference ranges without 
salt supplementation. However, renal function remained slightly 
impaired and at the age of two months first-grade chronic renal 
failure with CCr 37  ml/min was diagnosed. Voiding 
cistourethrography was performed and bilateral fifth-grade 
vesicoureteral reflux was diagnosed. By the age of three years, 
endoscopic treatment of bilateral vesicoureteral reflux with 
Deflux® had been performed. Control values of aldosterone and 
PRA were within reference values (Table 2).
Discussion
Differential diagnosis between PHA and other diseases based on 
serum electrolyte values includes hypoaldosteronism, adrenal 
hypoplasia and congenital adrenal hyperplasia (CAH). Normal 
hormone values, ACTH, 17-OH progesterone and cortisol rule 
out adrenal insufficiency. High values of aldosterone and cortisol 
are crucial for PHA diagnosis.2
Clinical signs of PHA, caused by electrolyte disturbance, are 
mainly non-specific and include poor feeding, vomiting, 
dehydration and electrolyte values similar to those in congenital 
adrenal hyperplasia.2,4,12
Treatment of renal PHA-1 includes sodium-chloride 
supplementation with gradual reduction of daily doses. 
Hyperkalaemia is usually moderate. Treatment of multiple PHA-1 
is more complex, and includes sodium supplementation (with 
sodium chloride or sodium bicarbonate) as well as early 
hyperkalaemia treatment (usually with ion exchange resins—
calcium resonium or sodium resonium). If this treatment is 
ineffective, indomethacin introduction should be considered. 
This inhibits prostaglandin synthesis, which results in decreased 
urine output and renal sodium losses. As recurrent respiratory 
infections can frequently occur, prophylactic use of antibiotics is 
sometimes recommended. In the case of feeding difficulties 
caused by severe gastro-oesophageal reflux, fundoplication 
with gastro- or jejunostomy should be performed.4 In secondary 
PHA-1, the resolution of clinical signs and normalisation of 
serum electrolyte levels is achieved after resolution of urinary 
tract infection or surgical treatment of urinary tract anomaly. 
However, partial reduction of distal tubule sensitivity to 
aldosterone can persist for some time (according to some 
studies 3–13  months) after surgical treatment. Therefore, tight 
control of weight gain and serum electrolyte levels is 
recommended for at least one year.7–9
Amin et al. showed follow-up results of five cases of renal PHA-1 
and two cases of multiple PHA-1. Patients with renal PHA-1 
underwent regular check-ups for up to 62 months and required 
a small amount of sodium supplementation in four cases. On the 
other hand, patients with multiple PHA-1, regularly followed up 
to 3.5 years of age, remained on sodium supplementation and 
indomethacin treatment.13
In our study, the first two cases described were diagnosed with 
renal PHA-1. Interestingly, in one case salt supplementation was 
performed for a short period (for 24 h) but in the second patient 
it was performed for 1.5  years. Also, in the first case severe 
respiratory acidosis as a result of pulmonary infection and not 
metabolic acidosis was observed.
Since Rodriguez-Soriano et al.14 established the entity of transient 
PHA-1 associated with obstructive uropathy in 1983, 60 cases 
have been described. A higher incidence of this entity is 
presumed, but this condition remains frequently undiagnosed 
because potassium levels are often only slightly elevated and 
aldosterone and renin levels are not routinely determined. 
Watanabe showed that all patients with this condition were 
younger than seven months, 80% had urinary tract malformations 
with urinary tract infection, 11.7% had a urinary tract 
malformation without urinary tract infection and 8.3% had only 
urinary tract infection. Transient PHA-1 probably occurs as a 
result of immature response of renal tubules to aldosterone. The 
incidence of transient PHA-1 decreases sharply after the third 
month of life. Prompt treatment of urinary tract infection is 
crucial in the prevention of kidney damage and possible 
complications of its delay are sepsis and septic shock. Therefore, 
in all cases of salt-wasting, urinalysis, urine culture and abdominal 
ultrasound should be performed.7,8,15
Because of oliguria and severe electrolyte disturbance, peritoneal 
dialysis was performed for five days in our patient with transient 
PHA-1. Unfortunately, after acute renal impairment, full renal 
function recovery was not achieved and first-grade chronic renal 
insufficiency developed. After that, this patient had two 
subsequent episodes of urinary tract infection without 
electrolyte disturbance, i.e. without clinical and laboratory 
parameters related to PHA.
All three patients showed improvements in appetite and 
adequate weight gain after discharge.
For technical reasons, we were not able to perform genetic 
analysis for any of our three patients.
In conclusion, in all patients with salt-wasting and dehydration 
differentiation between CAH and PHA should be performed. 
Also, in cases with hyperkalaemia, hyponatremia and metabolic 
acidosis, urinary tract infection and obstructive uropathy should 
be excluded. In some cases of PHA, long-term salt 
supplementation is required. Further studies are needed to 
improve our knowledge of this complex condition.
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